The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.
Lonafarnib (SCH66336) is a farnesyl transferase inhibitor (FTI) that inhibits the post-translational lipid modification of H-Ras and other farnesylated proteins. K- and N-Ras are also substrates of farnesyl transferase; however, upon treatment with FTIs, they are alternatively prenylated by geranylgeranyl transferase-1. Despite the failure to abrogate prenylation of K- and N-Ras, growth of many tumors in preclinical models is inhibited by FTIs. This suggests that the anti-proliferative action of FTIs is dependent on blocking the farnesylation of other proteins. Rheb (Ras homologue enriched in brain) is a farnesylated small GTPase that positively regulates mTOR (mammalian target of rapamycin) signaling. We found that Rheb and Rheb2 mRNA were elevated in various tumor cell lines relative to normal cells. Peptides derived from the carboxyl termini of human Rheb and Rheb2 are in vitro substrates for farnesyl transferase but not geranylgeranyl transferase-1. Rheb prenylation in cell culture was completely inhibited by SCH66336, indicating a lack of alternative prenylation. SCH66336 treatment also inhibited the phosphorylation of S6 ribosomal protein, a downstream target of Rheb and mTOR signaling. SCH66336 did not inhibit S6 phosphorylation in cells expressing Rheb-CSVL, a mutant construct of Rheb designed to be geranylgeranylated. Importantly, expression of Rheb-CSVL also abrogated SCH66336 enhancement of tamoxifen- and docetaxel-induced apoptosis in MCF-7 breast cancer cells and ES-2 ovarian cancer cells, respectively. Further, inhibition of Rheb signaling by rapamycin treatment, small interfering RNA, or dominant negative Rheb enhanced tamoxifen- and docetaxel-induced apoptosis, similar to FTI treatment. These studies demonstrated that Rheb is modified by farnesylation, is not a substrate for alternative prenylation, and plays a role in SCH66336 enhancement of the anti-tumor response to other chemotherapeutics.
Basso
Andrea D
AD
Department of Tumor Biology, Schering-Plough Research Institute, Kenilwort, New Jersey 07033, USA.
Mirza
Asra
A
Liu
Gongjie
G
Long
Brian J
BJ
Bishop
W Robert
WR
Kirschmeier
Paul
P
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D020169:Caspases / Q000378:metabolism; D045744:Cell Line, Tumor; D051231:Farnesyltranstransferase; D006801:Humans; D020559:Monomeric GTP-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D009369:Neoplasms / Q000188:drug therapy*; D009479:Neuropeptides / Q000235:genetics / Q000378:metabolism*; D010766:Phosphorylation; D010880:Piperidines / Q000378:metabolism*; D011494:Protein Kinases / Q000235:genetics / Q000378:metabolism*; D017368:Protein Prenylation; D011725:Pyridines / Q000378:metabolism*; D012333:RNA, Messenger / Q000378:metabolism; D000076205:Ras Homolog Enriched in Brain Protein; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology; D058570:TOR Serine-Threonine Kinases; D013629:Tamoxifen / Q000627:therapeutic use*; D043823:Taxoids / Q000627:therapeutic use*; D003986:Dibenzocycloheptenes
D019883:Alkyl and Aryl Transferases; D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D020169:Caspases; D051231:Farnesyltranstransferase; D020559:Monomeric GTP-Binding Proteins; D009479:Neuropeptides; D010880:Piperidines; D011494:Protein Kinases; D011725:Pyridines; D012333:RNA, Messenger; D000076205:Ras Homolog Enriched in Brain Protein; D011993:Recombinant Fusion Proteins; D058570:TOR Serine-Threonine Kinases; D013629:Tamoxifen; D043823:Taxoids; C490211:RHEB protein, human; C080625:taxane; C083291:geranylgeranyltransferase type-I; C546842:MTOR protein, human; C115354:lonafarnib; D003986:Dibenzocycloheptenes